SCHEMBL17520353

SCHEMBL17520353

CNC(=O)CCCCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1OC

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.73
HDAC3 O15379 16/20 0.73
HDAC4 P56524 16/20 0.73
HDAC1 Q13547 16/20 0.73
HDAC7 Q8WUI4 16/20 0.73
HDAC2 Q92769 16/20 0.73
HDAC10 Q969S8 16/20 0.73
HDAC11 Q96DB2 16/20 0.73
HDAC8 Q9BY41 16/20 0.73
HDAC6 Q9UBN7 16/20 0.73
HDAC9 Q9UKV0 16/20 0.73
HDAC5 Q9UQL6 16/20 0.73
EGFR P00533 3/20 0.69
RET P07949 1/20 0.69
KIF5B P33176 1/20 0.69
FGFR1 P11362 1/20 0.63
FLT1 P17948 1/20 0.63
FLT4 P35916 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19220779 0.91 HDAC3 (0.73) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL17520354 0.91 KDR (0.71) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL17520358 0.90 KDR (0.73) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL17520357 0.89 KDR (0.68) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL18979086 0.88 KDR (0.74) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL17520330 0.86 KDR (0.74) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4109645 0.85 KDR (0.80) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL1467590 0.85 KDR (0.78) KDREGFRRETKIF5BFGFR1
SCHEMBL14964748 0.84 KDR (0.82) KDREGFRRETKIF5BFGFR1
SCHEMBL1468281 0.84 KDR (0.82) KDREGFRRETKIF5BFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
CN-106660970-B Quinazoline derivatives 石药集团中奇制药技术(石家庄)有限公司 2020-07-10 CN disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885HDAC3 1036/4885HDAC4 933/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885HDAC3 1036/4885HDAC4 933/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885HDAC3 1036/4885HDAC4 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.